High-flying Vertex hikes CEO Reshma Kewalramani's pay by 30% to $20.6M

In a year in which Vertex Pharmaceuticals saw its share price swell by 41%, the Boston company rewarded its CEO in kind.

In her third full year as the CEO, Reshma Kewalramani, M.D., collected $20.6 million in total compensation in 2023, an increase of 30% from $15.9 million in 2022. Vertex reported its executive pay in a securities filing last week.